Kenvue (NYSE:KVUE) Posts Earnings Results, Meets Estimates

Kenvue (NYSE:KVUE) released its earnings results on Thursday. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26, Zacks reports. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue updated its FY 2025 guidance to 1.440-1.469 EPS.

Kenvue Stock Down 4.6 %

Shares of KVUE traded down $0.96 on Thursday, hitting $19.78. The company’s stock had a trading volume of 25,806,181 shares, compared to its average volume of 12,577,004. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $37.93 billion, a price-to-earnings ratio of 35.97, a P/E/G ratio of 2.05 and a beta of 1.45. The firm’s fifty day moving average price is $21.70 and its 200-day moving average price is $21.95. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 4.15%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Analyst Ratings Changes

KVUE has been the topic of a number of analyst reports. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. JPMorgan Chase & Co. upped their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Finally, Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.